NLGN1 and Alzheimer disease: They found a significative progressive decline in the levels of MPA4, NLGN1, and NRXN2a when comparing the diagnosed AD patients with those pre-diagnosed and both presented reduced levels of these molecules in relation to paired control patients that never developed AD symptoms [102].